Risheng Que

Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial

Xueli Bai, Xiang Li, Yiwen Chen, Guoliang Qiao et autres

cn (code pays fourni par la source)

5-Year survival rate over 20 % in pancreatic ductal adenocarcinoma: A retrospective study from a Chinese high-volume center

Xiang Li, Yiwen Chen, Guoliang Qiao, Jian Ni et autres

cn (code pays fourni par la source)

Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study

Chengxiang Guo, Weibo Du, Yiwen Chen, Wenbo Xiao et autres

INTRODUCTION: Standard treatments provide limited benefits for patients with intermediate- or advanced-stage hepatocellular carcinoma (HCC). This retrospective observational study aimed to assess the potential improvements in outcomes associated with systemic therapies in patients receiving transarterial chemoembolization (TACE) for initially unresectable HCC. METHODS: …

cn (code pays fourni par la source)

Updated results of the PATH study: Adjuvant therapy with donafenib plus a PD-1 inhibitor for patients with hepatocellular carcinoma at high risk of recurrence after resection.

Yiwen Chen, Yan Shen, Min Zhang, Jian Wu et autres

571 Background: There is no universally accepted standard treatment option or strategy for post-surgery adjuvant therapy in hepatocellular carcinoma (HCC). Among BCLC A/B patients (pts) with MVI, adjuvant transarterial chemoembolization has been reported to provide a 1-year recurrence-free survival (RFS) rate of …

cn (code pays fourni par la source)

5-Year Survival Rate Over 20% in Pancreatic Adenocarcinoma: A Retrospective Study from a High-Volume Center

Li Xiang, Xue-Li Bai, Guoliang Qiao, Yiwen Chen et autres

Survival Analysis of TACE Monotherapy vs. Combination Therapy in BCLC B and C Stage Hepatocellular Carcinoma: A Retrospective Cohort Study

Chengxiang Guo, Weibo Du, Yiwen Chen, Wenbo Xiao et autres

cn (code pays fourni par la source)

Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study

Yiwen Chen, Junlei Zhang, Wendi Hu, Xiang Li et autres

Evidences regarding the feasibility of transcatheter arterial chemoembolization (TACE)-based therapy for unresectable hepatocellular carcinoma (uHCC) remains limited. This study aimed to investigate the efficacy and safety of TACE combined with envafolimab and lenvatinib for uHCC. Eligible patients with uHCC received envafolimab and …

cn (code pays fourni par la source)

A Patient With Hepatocellular Carcinoma and Lung Metastasis Successfully Underwent Curative Surgery Following the Downstaging Treatment: A Case Report

Shiguo Xu, Ke Ma, Jianfeng Lu, Tao Wei et autres

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. Hepatic resection constitutes the major curative treatment option, but a significant proportion of patients are not surgical candidates on initial evaluation. Along with the development of novel therapeutic strategies including targeted therapies …

cn (code pays fourni par la source)

Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study.

Xueli Bai, Yiwen Chen, Junlei Zhang, Wendi Hu et autres

4108 Background: TACE-based conversion therapies are warranted for over 70% of patients with intermediate-advanced unresectable hepatocellular carcinoma (uHCC). This study aimed to investigate the efficacy and safety of envafolimab plus lenvatinib and TACE as conversion therapy in uHCC. Methods: This is an …

cn (code pays fourni par la source)

Adjuvant therapy with donafenib plus anti–PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study).

Yiwen Chen, Yan Shen, Min Zhang, Jian Wu et autres

e16228 Background: There is no universally accepted standard treatment option or strategy for post-surgery adjuvant therapy for HCC. Among BCLC A/B patients with MVI, adjuvant TACE provided a 1-year recurrence-free survival rate (RFSR) of around 60-70%. We conducted a pilot study to …

cn (code pays fourni par la source)

The safety and efficacy of donafenib combined with anti-PD-1 antibody as adjuvant therapy for patients (pts) with hepatocellular carcinoma (HCC): Updated results of a phase 2 study.

Yiwen Chen, Yan Shen, Min Zhang, Jian Wu et autres

e16202 Background: Adjuvant therapy may have an important role in decreasing recurrence rates and improve survival in selected pts with HCC following surgical resection. However, there is no standard treatment options or strategies. This study aimed to investigate the safety and efficacy …

cn (code pays fourni par la source)

ASO Visual Abstract: Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial

Qihan Fu, Yiwen Chen, Dabing Huang, Chengxiang Guo et autres

cn (code pays fourni par la source)